Antimicrobial mixtures ____________________________________________________________ _______________________________________ AREA OF INVENTION [0001] The present invention refers to the area of oral care and proposes new compositions for fighting plaque and biofilms on teeth. BACKGROUND OF THE INVENTION [0002] Nowadays the treatment of oral diseases, like caries or periodontitis is focused on preventive behavior. Thereby the reduction of plaque/biofilm and harm associated bacteria takes the center stage. The principal method is the mechanical removal of plaque and the use of toothpaste or mouthwashes that contain active ingredients that are known to control spe- cific bacteria found in dental plaque. One of these well-known antimicrobial active ingredi- ents is Carvacrol. [0003] Looking at the overall biofilm the complexity of a naturally formed biofilm is a huge challenge when it comes to the development of a suitable test systems. Thus, applied solu- tions with specific anti-biofilm properties are hardly known and rarely used. RELEVANT PRIOR ART [0004] EP 1830926 B1 (COLGATE) refers to a mixture that is efficacious as an antibacterial, antiplaque, anti-inflammatory, anti-oxidant, and anti-halitosis oral composition. The active in- gredient has one or more active compounds from an extract of oregano, such as thymol, car- vacrol and rosmarinic acid. The oral composition can be in the form of a mouth rinse; a denti- frice, including toothpaste, gels, powders; animal products; a film; or confectioneries, such as lozenges, and the like. [0005] WO 2006053458 A1 (GIVAUDAN) relates to bactericidal formulations that come into contact with human body, particularly wash formulations including liquid soaps, comprising perfume ingredients active against gram-negative bacteria, hydrotropes and surfactants. Such compositions contact the target site, for example the skin surface, only for a short time, usually not longer than 30 seconds. [0006] WO 2008 068683 A1 (FIRMENICH) concerns a flavoring composition for use in an oral care product, confectionary product or beverage. The composition includes an antimi- crobial key and optionally at least one flavoring ingredient of current use, wherein the anti- microbial key comprises 3,4-dimethylphenol together with one or more antimicrobial flavor ingredients each having a minimum inhibitory concentration of 1000 parts per million or less, against two or more strains selected from Fusobacterium nucleatum, Fusobacterium sp., Por- phyromonas gingivalis, Prevotella intermedia, Klebsiella pneumoniae, Veillonella alcalescens, Bacteroides melaninogenicus/forsythus, Selenomonas sputagena, Porphyromonas endodontalis, Prevotella melaninogenica and Streptococcus mutans. [0007] WO 2011055708 A1 (LION) refers to a liquid composition for the oral cavity contain- ing a nonionic surfactant, a wetting agent selected from among glycerin, propylene glycol, pol- yethylene glycols and sorbitol, 1-menthol, a para-hydroxybenzoate and a fragrance material selected from among 3-octanol, 3-octyl acetate, 3-octanone and fenchone. [0008] DE 102014221451 A1 (HENKEL) refers to oral and dental care and cleaning products, which - based on their weight - from 1 to 60 weight percent of at least one humectant selected from the group of sorbitol, glycerol or mixtures thereof, from 0.1 to 5 weight percent of at least one cooling agent from the group of menthol, menthyl lactate or mixtures thereof and 0.1 to 5 weight percent of an oily extract from the leaves of Rumex acetosa included, which show an improved cleaning performance and prevention of new plaque and also have a prolonged an- tibacterial effect. [0009] FR 3105732 A1 (EZAL) relates to a composition comprising Thymol or an essential oil comprising thymol; carvacrol or an essential oil comprising carvacrol, cineol or an essential oil comprising cineol, Eugenol or an essential oil comprising Eugenol, limonene, or an essential oil, comprising limonene and an aqueous gelling agent. It also relates to the use of this composi- tion as oral hygiene product and as a medicament, in particular for the treatment and/or pre- vention of an oral pathology and for preventing and/or reducing the formation of dental plaque. [0010] US 5,346,615 A (COLGATE) claims an antiplaque oral composition, such as a tooth- paste, gel dentifrice, tooth powder, mouthrinse or mouthwash, tooth hardener, anticalculus composition, gum or lozenge, comprises triclosan as an antiplaque component, the antiplaque action of which is unexpectedly and beneficially increased by the presence in the oral composi- tion of a phenolic flavoring agent, such as eucalpytol, thymol, methyl salicylate, menthol, phe- nol, halogenated derivatives thereof, and mixtures thereof. [0011] US 5,945,087 A (PFIZER) discloses oral rinse and dentifrice compositions, comprising a phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and a cyclodextrin. The compositions are useful in retarding the development of plaque, treating gingivitis, and in treating the presence of micro-organisms in the oral cavity. [0012] US 2009 163530 AA (LEUNG) claims edible films that include pullulan and anti- microbially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. [0013] US 2012 014884 AA (COLGATE) discloses novel uses of specific menthol-derivative compounds for methods of providing oral and systemic health care benefits, and methods of up-regulating or down-regulating periodontal disease metabolites. [0014] JP 2014 043441 A2 (SUNSTAR) provide a composition for oral cavity and a candida biofilm formation inhibitor containing geraniol and menthol. OBJECT OF THE INVENTION [0015] Therefore, it has been the object of the present invention providing new actives or active compositions capable of fighting biofilms, particularly plaque in the oral cavity, which are simultaneously • highly efficient even at low concentrations against all or at least most types of micro- organisms causing such biofilms, • mild to mucous membranes and • exhibit a pleasant taste of freshness. BRIEF DESCRIPTION OF THE INVENTION [0016] A first object of the present invention refers to an antimicrobial mixture comprising or (essentially) consisting of: (a) at least one flavoring agent, and (b) at least one physiological cooling agent, wherein said flavoring agent is selected from the group consisting of unsaturated 6- membered ring structures following formula (I) to (IX)

(VIII) (IX) [0017] wherein R, R1, R2 and R3 independently from each other stand for hydrogen, C1-C3 alkyl, or C3 alkenyl, C1-C3 alkoxy or acetate and n represent either zero or 1. [0018] Surprisingly new synergistic efficacy in fighting micro-organisms causing biofilms in the oral cavity was observed, when combining the above referenced flavoring agents in gen- eral, and carvacrol in particular with physiological cooling agents. The anti-microbial efficacy against decisive bacteria strains occurring in human saliva can be improved by this synergistic effect. The new mixtures are particularly active against bacterial strains selected from the group consisting of P. gingivalis, F. nucleatum, P. intermedia and/or S. mutans. The products are mild to mucous membranes and provide a fresh and pleasant taste. Flavoring agents [0019] In a preferred embodiment said unsaturated six-membered ring structures forming component (a) are selected from the group consisting of carvacrol, thymol, eugenol eugenyl acetate, dianthramide B, myrtenol, cumene alcohol and mixtures thereof and essential oils comprising at least one of said structures, such as for example thyme oil or oregano oil. [0020] Carvacrol, or cymophenol which is the preferred flavoring agent, is a monoterpenoid phenol having the characteristic warm odor of oregano. Carvacrol is present in the essential oil of Origanum vul- gare (oregano), oil of thyme, oil obtained from pepperwort, and wild bergamot. The essential oil of thyme subspecies contains between 5% and 75% of carvacrol, while Satureja (savory) subspecies have a content between 1% and 45%. Origanum majorana (marjoram) and Ditta- ny of Crete are rich in carvacrol, 50% and 60–80% respectively. It is also found in tequila and Lippia graveolens (Mexican oregano) in the verbena family. Carvacrol is charac- terized by a strong disinfectant, fungicidal and bactericidal effect and is used in mouthwash- es, toothpaste and in alcoholic solution for skin disinfection because of its pleasant taste (cf. Heinz Lüllmann, Klaus Mohr, Lutz Hein: Pharmakologie und Toxikologie, Georg Thieme, Stuttgart, 2010, p.451.) [0021] Thymol (also known as 2-isopropyl-5-methylphenol, IPMP), is a natural monoterpenoid phenol derivative of p-Cymene, isomeric with carvacrol, found in oil of thyme, and extracted from Thymus vulgaris (common thyme), ajwain, and various other plants as a white crystalline substance of a pleasant aromatic odor and strong antisep- tic properties. Thymol also provides the distinctive, strong flavor of the culinary herb thyme, also produced from T. vulgaris. [0022] Eugenol is an allyl chain-substituted guaiacol. It is a colorless to pale yellow, aromatic oily liquid ex- tracted from certain essential oils especially from clove, nutmeg, cinnamon, basil and bay leaf. It is present in concentrations of 80–90% in clove bud oil and at 82–88% in clove leaf oil. Eugenol has a pleasant, spicy, clove-like scent. The name is derived from Eugenia caryophyl- lata, the former Linnean nomenclature term for cloves. The currently accepted name is Syzygium aromaticum. [0023] Eugenyl acetate also known as acetyl eugenol is a phenylpropanoid compound found in cloves. It is the second in abundance to the related compound eugenol in certain extract preparations. Like eugenol, it is found in several plants such as Acacia nilotica and Piper betle and has similar antibacterial and antifungal properties on C. albicans and S. mutans. It inhibits aggregation of platelets and has partial agonistic ac- tivity on AhR. [0024] Myrtenol is a bio-active isolate of Taxus Physiological cooling agents [0025] Said physiological cooling agents, forming component (b) are preferably selected from the group formed by the species depicted in the following table (including their optical isomers and racemates): [0026] A first important representative of the substances forming component (b) is mono- menthyl succinate, which as a substance was patented as early as 1963 by Brown & William- son Tobacco Corp. (US 3,111,127) and as a refrigerant is the subject of property rights US 5,725,865 and 5,843,466 (V.Mane Fils). Both the succinate and the analogous monomenthyl glutarate are important representatives of monomenthyl esters based on di- and polycarbox- ylic acids: [0027] Examples of applications of these substances can be found, for example, in the print- ed documents WO 2003043431 (Unilever) or EP 1332772 A1 (IFF). [0028] The next important group of menthol compounds preferred in the sense of the inven- tion comprises carbonate esters of menthol and polyols, such as glycols, glycerol or carbohy- drates, such as menthol ethylene glycol carbonates, menthol propylene glycol carbonates, menthol 2-methyl-1,2-propanediol carbonates or the corresponding sugar derivatives: [0029] The use of such substances as a cooling agent for cigarettes is, for example, the sub- ject of the 1968 publication US 3,419,543 (Mold et al.); their use as a physiological cooling agent is claimed in DE 4226043 A1 (H&R). [0030] In the sense of the invention, the menthol compounds menthyl lactate) and, in partic- ular, menthone glyceryl acetal or menthone glyceryl ketal are preferred. [0031] The former structure is obtained by esterification of lactic acid with menthol, the latter by acetylation of menthone with glycerol (cf. DE 2608226 A1, H&R). This group of com- pounds also includes 3-(l-menthoxy)-1,2,propanediol, also known as Cooling Agent 10 (US 6,328,982, TIC), and 3-(l-menthoxy)-2-methyl-1,2,propanediol, which has an additional methyl group.

[0032] For example, 3-(l-menthoxy)-1,2,propanediol is prepared starting from menthol ac- cording to the following scheme (see US 4,459,425, Takasago): [0033] Alternative routes in which menthol is reacted with epichlorohydrin in the first step are described in US 6,407,293 and US 6,515,188 (Takasago). The following is an overview of preferred menthol compounds characterized by CO bonding:

[0034] Among these substances, menthone glyceryl acetal/ketal and menthyl lactate as well as menthol ethylene glycol carbonate and menthol propylene glycol carbonate. [0035] In the 1970s, menthol compounds were developed for the first time which have a C-C bond in the 3-position and of which a number of representatives can also be used in the sense of the invention. These substances are generally referred to as WS types. The basic body is a menthol derivative in which the hydroxyl group is replaced by a carboxyl group (WS-1). All other WS types are derived from this structure, such as the species WS-3, WS-4, WS-5, WS-12, WS-14 and WS-30, which are also preferred in the sense of the invention. The following two diagrams show the synthesis routes:

[0036] The esters derived from WS-1 are described, for example, in US 4,157,384, and the corresponding N-substituted amides in J. Soc. Cosmet. Chem. pp.185-200 (1978). [0037] The preferred physiological cooling agents encompass menthyl lactate, menthyl pro- pylene glycol carbonate, menthone glyceryl acetal/ketal and 3-(-)-Menthoxy)propane-1,2- diol. [0038] In another preferred embodiment components (a) and (b) can be present in ratios by weight of from about 1:99 to about 99:1, preferably 10:90 to about 90:10, preferably from about 20:80 to about 80:20 and more preferred from about 40:60 to about 60:40. Solvents [0039] In another preferred embodiment the mixtures according to the present invention may include solvents such as for example water, ethanol or glycerol or mixtures thereof. In case solvents are present, their amount ranges typically from about 5 to about 95 wt.- percent, preferably from about 10 to about 75 wt.-percent and more preferably from about 25 to about 50 wt.-percent. ORAL COMPOSITIONS [0040] Another object of the present invention is directed to a preferably non-therapeutic oral and/or oral care composition. Typical examples for suitable oral compositions encom- pass, toothpastes, mouth washes, (dental) chewing gums, (hard boiled) candies, and com- pressed tablets. The manufacture and composition of said oral compositions are described as follows: Toothpastes and mouthwashes [0041] Toothpastes or tooth creams are generally understood to be paste-like preparations of water, thickeners, humectants, abrasives or polishes, surfactants, sweeteners, flavorings, deodorizing agents and agents active against oral and dental diseases. In toothpastes ac- cording to the invention, any of the usual polishes may be used, such as chalk, dicalcium phosphate, insoluble sodium metaphosphate, aluminium silicates, calcium pyrophosphate, finely particulate synthetic resins, silicas, aluminium oxide and aluminium oxide trihydrate. Particularly suitable polishes for toothpastes according to the invention are finely particulate xerogel silicas, hydrogel silicas, precipitated silicas, aluminium oxide trihydrate and finely par- ticulate.alpha-alumina, or mixtures of these polishes. Such polishes are preferably used in quantities of from about 15 to 40% by weight of the toothpaste. Preferred humectants used for toothpastes according to the invention include low molecular weight polyethylene gly- cols, glycerol, sorbitol or mixtures thereof in quantities of up to about 50% by weight of the toothpaste. Among the known thickeners for use with toothpastes according to the inven- tion, particularly preferred are the thickening, finely particulate gel silicas and nonionic hy- drocolloids, such as hydroxy ethyl cellulose, hydroxy propyl guar, hydroxy ethyl starch, poly- vinyl pyrrolidone, high molecular weight polyethylene glycol and vegetable gums, such as tragacanth, agaragar, carrageen moss, gum arabic and xanthan gum. The desired flavor and aroma for preparations in accordance with the invention may be obtained by adding the components (a) and/or (b) and optionally also (c). It is also advantageous adding caries inhib- itors to the oral preparations in the form of, for example, alkali fluorides, alkali monofluoro- phosphates or alkali salts of organophosphonic acids. In addition, the oral preparations ac- cording to the invention may contain other standard auxiliaries, such as dyes, preservatives and opacifiers, for example titanium dioxide. For mouthwashes, the oral compositions ac- cording to the invention may readily be combined with aqueous-alcoholic solutions contain- ing different amounts of ethereal oils, emulsifiers, astringent and toning drug extracts, caries- inhibiting additives and flavor correctants. Chewing gums [0042] Chewing gums typically consist of a water- insoluble vase component, a water- soluble component and additives providing for example a specific flavour. [0043] The water-insoluble base, which is also known as the "gum base", typically compris- es natural or synthetic elastomers, resins, fats and oils, plasticizers, fillers, softeners, dyes and optionally waxes. The base normally makes up 5 to 95% by weight, preferably 10 to 50% by weight and more particularly 20 to 35% by weight of the composition as a whole. In one typi- cal embodiment of the invention, the base consists of 20 to 60% by weight synthetic elasto- mers, 0 to 30% by weight natural elastomers, 5 to 55% by weight plasticizers, 4 to 35% by weight fillers, 5 to 35% by weight softeners and small amounts of additives, such as dyes, antioxidants and the like, with the proviso that they are soluble in water at best in small quantities. [0044] Suitable synthetic elastomers are, for example, polyisobutylenes with average mo- lecular weights (as measured by GPC) of 10,000 to 100,000 and preferably 50,000 to 80,000, isobutylene/isoprene copolymers ("butyl elastomers"), styrene/butadiene copolymers (sty- rene:butadiene ratio, for example, 1:3 to 3:1). polyvinyl acetates with average molecular weights (as measured by GPC) of 2,000 to 90,000 and preferably 10,000 to 65,000, polyiso- prenes, polyethylenes, vinyl acetate/vinyl laurate copolymers and mixtures thereof. Examples of suitable natural elastomers are rubbers, such as for example smoked or liquid latex or gua- yuls, and natural gums, such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosindinba, chicle, gutta hang kang and mixtures thereof. The choice of the synthetic and natural elastomers and their mixing ratios essentially depends on whether or not bubbles are to be produced with the chewing gums (bubble gums). Elas- tomer mixtures containing jelutong, chicle, sorva and massaranduba are preferably used. [0045] In most cases, the elastomers are too hard or lack plasticity for satisfactory pro- cessing, so that it has been found to be of advantage to use special plasticizers which, of course, must also satisfy in particular all requirements relating to acceptability as food addi- tives. In this respect, suitable plasticizers are, above all, esters of resin acids, for example es- ters of lower aliphatic alcohols or polyols with completely or partly hydrogenated, monomer- ic or oligomeric resin acids. In particular, the methyl, glycerol or pentaerythritol esters or mix- tures thereof are used for this purpose. Alternatively, terpene resins, which may be derived from .alpha.-pinene, .beta.-pinene, .delta.-limonene or mixtures thereof, could also be used. [0046] Suitable fillers or texturizers are magnesium or calcium carbonate, ground pumice stone, silicates, especially magnesium or aluminium silicates, clays, aluminium oxides, talcum, titanium dioxide, mono-, di- and tricalcium phosphate and cellulose polymers. [0047] Suitable softeners or emulsifiers are tallow, hydrogenated tallow, hydrogenated or partly hydrogenated vegetable oils, cocoa butter, partial glycerides, lecithin, triacetin and saturated or unsaturated fatty acids containing 6 to 22 and preferably 12 to 18 carbon atoms and mixtures thereof. [0048] Suitable dyes and whiteners are, for example, the FD&C types, plant and fruit ex- tracts permitted for coloring foods and titanium dioxide. The gum bases may also contain waxes or may be wax-free [0049] In addition to the water-insoluble gum base, chewing gum preparations regularly contain a water-soluble component which is formed, for example, by softeners, sweeteners, fillers, flavours, flavour enhancers, emulsifiers, dyes, acidifiers, antioxidants and the like, with the proviso that the constituents have at least adequate solubility in water. Accordingly, indi- vidual constituents may belong both to the water-insoluble phase and to the water-soluble phase, depending on the water solubility of the special representatives. However, combina- tions may also be used, for example a combination of a water-soluble and a water-insoluble emulsifier, in which case the individual representatives are present in different phases. The water-insoluble component usually makes up 5 to 95% by weight and preferably 20 to 80% by weight of the preparation. [0050] Water-soluble softeners or plasticizers are added to the chewing gum compositions to improve chewability and the chewing feel and are present in the mixtures in quantities of typically 0.5 to 15% by weight. Typical examples are glycerol, lecithin and aqueous solutions of sorbitol, hydrogenated starch hydrolysates or corn sirup. [0051] Fillers are particularly suitable for the production of low-calorie chewing gums and may be selected, for example, from polydextrose, raftilose, raftilin, fructo-oligosaccharides (NutraFlora), palatinose oligosaccharides, guar gum hydrolyzates (Sun Fiber) and dextrins. [0052] The chewing gums may additionally contain auxiliaries and additives which are suit- able, for example, for dental care, more particularly for controlling plaque and gingivitis, such as for example chlorhexidine, CPC or triclosan. They may also contain pH adjusters (for ex- ample buffer or urea), anti-caries agents (for example phosphates or fluorides), biogenic agents (antibodies, enzymes, caffeine, plant extracts), providing these substances are permit- ted in foods and do not undesirably interact with one another. Candies [0053] According to the present invention the preferred candies are so-called hard-boiled candies. Their bases are usually prepared from a mixture of sugar and other carbohydrates that are kept in an amorphous or glassy condition. This form can be considered a solid syrup of sugars generally having up to about 4.5 % b.w. moisture, based on the weight of the can- dy base, with about 0.5 to about 2.5 % b.w. being preferred and about 1.0 to about 1.5 % b.w. being most preferred. Such materials normally contain up to 65 % b.w. corn syrup, up to 80 % b.w. sugar and from 0.1 to 5.0 % b.w. water. Generally, the ratio of sugar (or other sweetener suitable for candy formulation) to corn syrup is within the range of about 70:25 to about 45:55 with about 60:40 being preferred. The syrup component generally is prepared from corn syrups high in fructose, but may include other materials. Further ingredients such as flavorings, sweeteners, acidulants, colorants and so forth may also be added. [0054] Hard boiled candy bases may also be prepared from non-fermentable sugars such as sorbitol, mannitol, xylitol, maltitol, hydrogenated starch hydrolysate, hydrogenated corn syrup and mixtures thereof. The candy bases may contain up to about 95% sorbitol, a mixture of sorbitol and mannitol at a ratio of about 9.5 to 0.5 up to about 7.5 to 2.5 and hydrogenat- ed corn syrup up to about 55% of the syrup component. Compressed tablets [0055] According to the present invention the oral compositions can represent compressed tablets, comprising the liquid flavor in amounts of typically about 0.1 to about 0.6 % b.w. and preferably about 0.5 % b.w. Additives [0056] The oral compositions of the present invention may include additional additives as for examples aroma compounds, sweeteners or vitamins, in amounts of from about 0.1 to about 10 % b.w. These additives may also represent components of the respective medica- ments. Aroma compounds [0057] Aroma compounds are selected from Anethol, Acetanisol, Acetaldehyde, Acetylme- thylcarbinol, Acetylpyrazin-2, Acetylpyridine-2, Acethylthiazoline-2, Acethylthiazole-2, Al- lylcapronate, Amylzimtaldehyde-alpha, Anisaldehyde-para, Anisalcohol, Dimethylisopropyl- dithiazine, Benzaldehyde, Benzylacetate, Borneol-l, Butiric acid, Butylacetate, Butylidenphta- lide-3, Capric acid, Carvacrol, Carvone-l, Carvone-d, Carvomenthone, Carvylacetate-cis, Cary- ophyllene, Cineol-1,8, Cineol-1,4, Cinnamylacetate, Citral, Citronellal, Citronellol, Citronel- lylacetate, Cuminaldehyde, Cyclopentadecanolide, Damascone-alpha, Damascone-beta, Damascenone-alpha, Damascenone-beta, Decalactone delta, Decalactone-gamma, Dehy- dromenthofurolactone, Dihydromenthofurolactone, Diethylpyrazine-2,3, Dihydroanethol, Dihydrocarvone, Dihydrocoumarine, Dihydroionone-beta, Dimethylanthranilate, Dimethyl- sulfide, Dimethylpyrazine, Sotolon, Diphenyloxide, Divanilline, Decadienal-2,4, Dodecalacton- delta, Dodecalactone-gamma, Acetic acid, Ethylacetate, Ethylbutyrate, Ethylmethylbutyrate-2, Ethylcapronate, Ethylcaprylate, Ethylcinnamate, Ethylisobutyrate, Ethylvanilline, Ethyllactate, Ethylmaltol, Ethylmethylthiopropionate, Ethylphenol-4, Ethylisovalerianate, Eugenol, Fenchol, Furaneol, Filbertone, Frambinone, Frambinonmethylether, Furfurylthiol, Undecatriene, Gerani- ol, Geranylacetate, Geranylisobutyrate, Guaiacol, Heliotropine, Heptanon-2, Heptenal-Z-4, Hexalactone-gamma, Heptalactone-gamma, Hexenol-Z-3, Hexenol-E-2, Hexanol, Hex- ylacetate, Hexenylacetate-Z-3, Hexenylacetate-E-2, Hexylzimtaldehyde-alpha, Hexen- ylcapronate-Z-3, Hotrienol, Indol, Irone-alpha, Ionone-alpha, Ionone-beta, Isoamylacetate, Isoamylbutyrate, Isoamylisovaerianate, Isobutylacetate, Isobutylthiazol, Isobutyraldehyde, Isovaleraldehyde, Isoeugenol, Isomenthone, Isopropylmethoxypyrazine, Isobutylmethoxypy- razine, Isopropylmethylpyrazine-2,4, Isopulegol, Jasminlactone, Jasmone cis, Campfor, Ke- toisophorone, Cresol, Limonene-d, Linalool-l, Linalool-d, Linalylacetate, Linalooloxide, Maltol, Methylcyclopentenolone, L-Menthone, D-Menthone, L-Menthol, D-Menthol, Neo Menthol, L- Menthylacetate, D Menthylacetate, Massoilactone, Melonal, Menthenthiol-1,8, Epithiomen- than-1,8, Thiomenthanon-8,3, Menthofurolactone, Menthadienylacetate, Methoxymethylpy- razin-2,3, Methylanthranilate, Methylsalicylate, Thymol, Methylbutyrate, Methylbutylacetate- 2, Methylcinnamate, Methylfuranthiol-2,3, Methyltetrahydrofuranthiol-2,3, Methyljasmonate, Methyldihydrojasmonate, Methylthiobutyrate, Methylthiohexylacetate-1,3, Methylthiohexa- nol-1,3, Methional, Myrtenal, Naringin, Neral, Nerol, Nerylacetate, Nonalactone-gamma, Nonalactone-delta, Nonenal-E-2, Nonenal-Z-6, Nonenol-Z-6, Nootkatone, Dihydronoot- katone, Octenol-1,3, Octalactone-gamma, Octalactone-delta, Pelitorine, Pentenone-1,3, Pen- tylacetate, Phenylacetaldehyde, Phenylethylalcohol, Phenylethylacetate, Piperitanat, Prenyl- thiol, Prenylthioacetate, Rosenoxide, Rubenamine, Rubescenamine, Sabinenhydrate, Scatol, Styrolylacetate, Terpineol, Terpinenol-4, Thiohexanol-1,3, Thiohexylacetate-1,3, Thiopenta- none-4,4,2, Trimethylpyrazine, Undecalactone-gamma und delta, Decadienal-2,4, Nonadi- enal-2,4, Nonadienal-2,6, Undecadienal-2,4, Vanilline, Vinylguaiacol, Whiskylactone, Cinnam- icaldehyde, Cinnamicalcohol, Diallyldisulfide, Allylisothiocyanate, Hexanal, E-2-Hexenal, Oc- tanal, Decanal, Tridecatrienal, 12-Methyltridecanal, Pinene-alpha, Pinene-beta, Piperitone as well as their mixtures. Sweeteners [0058] Suitable sweet-tasting substances, including natural sources of these substances (component e5), such as for example sweet-tasting carbohydrates or sugars (e.g. sucrose (synonymous with saccharose), trehalose, lactose, maltose, melezitose, raffinose, palatinose, lactulose, D-fructose, D-glucose, D-galactose, L-rhamnose, D-sorbose, D-mannose, D- tagatose, D-arabinose, L-arabinose, D-ribose, D-glyceraldehyde, maltodextrin) or vegetable preparations containing predominantly these carbohydrates (e.g. from sugar beet (Beta vul- garis ssp., sugar fractions, sugar syrup, molasses), from sugar cane (Saccharum officinarum ssp., e.g. molasses, sugar syrups), from sugar maple (Acer ssp.), from agave (agave thick juice), synthetic/enzymatic hydrolysates of starch or sucrose (e.g. invert sugar syrup, highly enriched fructose syrups made from corn starch), fruit concentrates (e.g. from apples or pears, apple syrup, pear syrup), sugar alcohols (e.g. erythritol, threitol, arabitol, ribitol, xylitol, sorbitol, mannitol, dulcitol, lactitol), proteins (e.g. miraculin, monellin, thaumatin, curculin, brazzein), sweeteners (magap, sodiumcyclamate, acesulfame K, neohesperidin dihydrochal- cone, saccharin sodium salt, aspartame®, superaspartame, neotame, alitame, sucralose, ste- vioside, rebaudioside, lugduname, carrelame, sucrononate, sucrooctate, monatin, phyllodul- cin), certain sweet-tasting amino acids (glycine, D-leucine, D-threonine, D-asparagine, D- phenylalanine, D-tryptophan, L-proline), other sweet-tasting low-molecular substances (e.g. hernandulcin, dihydrochalcone glycosides, glycyrrhizin, glycyrrhetinic acid ammonium salt or other glycyrrhetinic acid derivatives), liquorice extracts (Glycyrrhizza glabra ssp.), Lippia dulcis extracts, Momordica ssp. extracts or individual substances (in particular Momordica grosven- ori [Luo Han Guo] and the mogrosides obtained therefrom), Hydrangea dulcis or Stevia ssp. (e.g. Stevia rebaudiana) extracts or individual substances. Vitamins [0059] In another embodiment of the present invention the compositions may include vit- amins. Vitamins have diverse biochemical functions. Some have hormone-like functions as regulators of mineral metabolism (e.g., vitamin D), or regulators of cell and tissue growth and differentiation (e.g., some forms of vitamin A). Others function as antioxidants (e.g., vitamin E and sometimes vitamin C). The largest numbers of vitamins (e.g. B complex vitamins) act as precursors for enzyme cofactors that help enzymes in their work as catalysts in metabolism. In this role, vitamins may be tightly bound to enzymes as part of prosthetic groups: For ex- ample, biotin is part of enzymes involved in making fatty acids. Vitamins may also be less tightly bound to enzyme catalysts as coenzymes, detachable molecules that function to carry chemical groups or electrons between molecules. For example, folic acid carries various forms of carbon group – methyl, formyl, and methylene – in the cell. Although these roles in assist- ing enzyme-substrate reactions are vitamins' best-known function, the other vitamin func- tions are equally important. In the course of the present invention suitable vitamins are se- lected from the group consisting of • Vitamin A (retinol, retinal, beta carotene), • Vitamin B1 (thiamine), • Vitamin B2 (riboflavin), • Vitamin B3 (niacin, niacinamide), • Vitamin B ₅ (panthothenic acid), • Vitamin B ₆ (pyridoxine, pyridoxamine, paridoxal), • Vitamin B7 (biotin), • Vitamin B9 (folic acid, folinic acid), • Vitamin B ₁₂ (cyanobalamin, hydoxycobalmin, methylcobalmin), • Vitamin C (ascorbic acid), • Vitamin D (cholecalciferol), • Vitamin E (tocopherols, tocotrienols), and • Vitamin K (phyolloquinone, menaquinone). [0060] The preferred vitamins are ascorbic acid and tocopherols. Said vitamins may be pre- sent in the food composition in amounts of about 0.1 to about 5 % b.w., and preferably about 0.5 to about 1 % b.w. INDUSTRIAL APPLICATION [0061] Another object of the present invention refers to a method for fighting micro- organisms causing biofilms and/or plaque in the oral cavity comprising or consisting of the following steps: (a) providing a mixture as described above; (b) incorporating said mixture into an oral composition; and (c) bringing said oral composition in contact with the oral cavity of a human. [0062] The invention also encompasses the use of the mixture as described above for oral care applications, namely fighting of microorganisms causing biofilms and/or plaque in the oral cavity. In the context of the present invention oral care applications refers to products such as tooth pastes, mouthwashes, (dental) chewing gums and candies. [0063] In a preferred embodiment the mixture contains or consists of carvacrol as the flavor- ing agent and menthyl lactate, menthyl propylene glycol carbonate, 3-(-)menthoxypropane- 12-diol or mixtures thereof as the physiological cooling agent [0064] For the sake of good order, it is emphasized that all preferred embodiments, ranges, combinations and the like mentioned above refer as well to the claimed method and uses. A repetition is therefore not necessary.

EXAMPLES ____________________________________________________________ _______________________________________ Examples 1 to 23 Determination of Minimum Inhibitory Concentration (MIC) data in vitro [0065] MIC data were evaluated based on DIN 58940-8 micro dilution method. For the ex- periments three relevant bacteria occurring in the oral biofilm were selected: Streptococcus mutans (DSM 20523, ATCC 25175), Porphyromonas gingivalis (DSM 20709, ATCC33277), and Prevotella intermedia (DSM 20706, ATCC25611). [0066] All test organisms were cultivated in suitable complex medium and under anaerobic and/or microaerophilic conditions. Every test substance was applied as technical triplicate on a 96 microtiter plate in a total volume of 300 µL per well. The inoculum was directly trans- ferred from a glycerin stock solution or from a freshly prepared preculture. Therefore 15 mL reagent tubes were filled with specific complex growth medium and inoculated with skim milk stocks of single strains. The incubation was done at 37°C up to 48 h until an OD620 > 0.1 -1.0. Suspensions were controlled microscopically. In both cases the bacteria were transferred and diluted to fresh complex medium on a 96 well plate. [0067] Test substances were either the pure materials or mixtures. The mixtures contain a cooling compound and an aroma component according to claims. Further these effective building blocks can be included in an aroma composition. Therefore, nature identical (syn- thetic) bases (base nature identical A/B) and/or natural basic formulations (base natural A/B) can be added. [0068] Test substances were 100-fold solved in dimethyl sulfoxid (DMSO) and diluted directly on the 96 well plate. As negative controls farnesol and/or triclosan were applied in appropri- ate concentrations from 1 to 100 ppm. An untreated medium control was applied as growth control. The incubation of the test plates was done for 16-24 h at 37°C. At the end of the ex- periment, growth was determined photometrically by detecting OD ₆₂₀ values using Sunrise Photometer (TECAN, Austria). Mean values of triplicates were calculated and normalized with blank values (growth medium with or without test substances). The growths of treated wells were evaluated in relation to the growth control. Minimum inhibition concentrations (MIC) was defined as minimal concentration that causes a complete inhibition of bacterial growth. [0069] Synergies were calculated using the following formula; MIC stands for minimum in- hibitory concentration The formula can be modified according to the number of components per mixture. MICmix = MIC value of mixture PA = Percentage of component A MIC A = MIC value of component A PB = Percentage of component B MIC B = MIC value of component B A synergism is given if the resulting value is below 1. Ex vivo Biofilm Model [0070] The experiment was developed following the method described in WO2018/033211 and Kistler et al (Kistler et al.2015). [0071] Up to 50 subjects were recruited for saliva donation. Participants were between 18 and 65 years old and medically healthy. Subjects who had taken antibiotics, ate antimicrobial food such as garlic within last 24 h and/or had suffer from any systemic conditions that may affected their immune or inflammatory status, were excluded from the study. Fresh morning saliva from all donors were selected and pooled. All volunteers were asked to refrain from drinking, eating, or brushing their teeth bevor donating by expectoration into sterile universal tubes. [0072] The Calgary Biofilm Device (CBD) was originally developed for medical usage. It is commercially available as MBEC (Minimum Biofilm Eradication Concentration) Biofilm Inocu- lator and it is suitable as a basis for biofilm research (Kistler et al. 2015; Ceri et al. 1999). The 96 pegs of the device lid were coated with hydroxylapatite and mimic teeth. It was fitted to a second 96 well plate in a way that the pegs were in contact with saliva. The CBD was incubat- ed under anaerobic conditions for 18 hours at 37°C. After that the lid was transferred to a new baseplate containing Oral care medium (Brain Heart Infusion broth (Merck) supplement- ed with pig stomach mucin (1 g/L), haemin (10 mg/L), and menadion (0.5 mg/L). The growth medium was changed every day. [0073] Stock solutions of all test substances were prepared in dimethylsulfoxid (DMSO). For the working concentration the stocks were diluted in NaCl-solution or other solvents. If nec- essary, a treatment in the sonification bath or heater could be applied. Pure NaCl-solution was used as positive biofilm growth control. The treatment was done 4 times within 2 days for 2 min at 37°C and 300 rpm. After the treatment the pegs were washed with pure NaCl solution under same conditions and then again transferred to the growth medium. Six repli- cates were applied on each plate for every test substance and concentration. At the end the pegs were washed again, and microbial activity was quantified photometrically by fluorescein diacetate (FDA) hydrolysis. FDA is converted into fluorescein by protease, lipase, and esterase activities in the biofilm, thus the quantification of fluorescein represents the activity of the biofilm. [0074] Table 1 provides the results for minimal inhibition concentrations for various mixtures of carvacrol and physiological cooling agents and the related synergy indices. Figure 1 shows results for the relative biofilm activity after respective treatments of several single compo- nents. [0075] References Kistler, James O.; Pesaro, Manuel; Wade, William G. (2015): Development and pyrosequencing analysis of an in-vitro oral biofilm model. BMC microbiology 15, p. 24. [0076] Ceri, H.; Olson, M. E.; Stremick, C.; Read, R. R.; Morck, D.; Buret, A. (1999): The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacte- rial biofilms. Journal of clinical microbiology 37 (6), p. 1771–1776. Table 1 Antimicrobial efficacy and synergisms for various combinations, calculated for different bacteria strains, calculated with measured MIC value of the mixture (MIC mix), measured MIC value of compo- nent A (MIC A), percentage of component A in the mixture (PA), measured MIC value of component B (MIC B), percentage of component B in the mixture (PB), calculated synergistic indices (SI) Table 2 Antimicrobial efficacy and synergisms for specific synthetic mixtures (product examples), calculated with measured MIC value of the mixture (MIC mix), measured MIC value of component A (MIC A), per- centage of component A in the mixture (PA), measured MIC value of component B (MIC B), percentage of component B in the mixture (PB), measured MIC value of component C (MIC C), percentage of component C in the mixture (PC), calculated synergistic indices (SI) Table 3 Antimicrobial efficacy and synergisms for specific synthetic mixtures (product examples), calculated with measured MIC value of the mixture (MIC mix), measured MIC value of component A (MIC A), per- centage of component A in the mixture (PA), measured MIC value of component B (MIC B), percentage of component B in the mixture (PB), measured MIC value of component C (MIC C), percentage of ^{component C in the mixture (PC), calculated synergistic indices (SI).} s s s Figure 1 shows effective oral biofilm reduction. The figure shows the results for the relative biofilm activity after respective treatments with various flavouring agents. Figure 1 shows concentration dependent oral biofilm reduction after respective treatment with Carvacrol and Oregano oil. The figure shows the remaining relative biofilm activity com- pared to control after the treatments. FORMULATION EXAMPLES [0077] The following Tables 4 to 8 provide various examples for oral compositions [0078] Table 4 Chewing gum, free of sugar; all amounts in % b.w.

[0079] Table 5 Tooth paste; all amounts in % b.w.

[0080] Table 6 Mouth wash concentrate; all amounts in % b.w. [0081] Table 7 Hard boiled candy, sugar-free; all amounts in % b.w. [0082] Table 8 Hard boiled candy; all amounts in % b.w.